Table 1.
Demographics and treatment details of patients with glioblastoma multiforme
| Total | 9 |
|---|---|
| Sex | |
| Female | 3 (33%) |
| Male | 6 (67%) |
| Age, years | |
| Median | 67 |
| Range | 44–81 |
| Karnofsky performance score at presentation | |
| 80 | 3 (33%) |
| 90 | 6 (67%) |
| Histology proven GBM | 9 (100%) |
| Surgical resection | |
| Gross total resection | 3 (33%) |
| Partial resection | 5 (56%) |
| Biopsy | 1 (11%) |
| Tumor volume treated | |
| − CTV | |
| Mean | 93.88 cm3 |
| Range | 9.04–330.7 cm3 |
| − PTV | |
| Mean | 205.72 cm3 |
| Range | 82.5–375.8 cm3 |
| Adjuvant chemotherapy | |
| TMZ | 9 (100%) |
| TMZ + Avastina | 4 (44%) |
| Thrombocytopenia with adjuvant TMZ | 2 (22%) |
| Tumor lateralization | |
| Left | 5 (56%) |
| Right | 3 (33%) |
| Multiple | 1 (11%) |
| Tumor location | |
| Frontal | 3 (33%) |
| Fronto-temporal | 1 (11%) |
| Temporal | 3 (33%) |
| Parietal | 1 (11%) |
| Multiple | 1 (11%) |
CTV = clinical target volume, GBM = glioblastoma multiforme, PTV = planned target volume, TMZ = temozolomide.
a
Genentech, San Francisco, CA, USA.